相关实验视频

Updated: Jun 28, 2025

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

Published on: April 17, 2020

治疗模式和T4b食道癌的存活率:一个回顾性队列研究

Bin-Bin Yu¹, Jiang-Qiong Huang¹, Huan-Wei Liang¹

¹Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China.

|April 21, 2024

概括

与化疗放射治疗相比,手术可以改善T4b期食道癌患者的生存率. 这包括更好的癌症特异性存活率 (CSS) 和整体存活率 (OS).

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
胃肠道瘤学胃肠道瘤学

背景情况:

胃管癌T4b阶段是局部发达的,并带来了重大治疗挑战.
这一阶段的治疗策略往往涉及多种方法的组合,但最佳方法仍在争论中.

研究的目的:

评估不同治疗方法对T4b期食道癌的比较疗效.
在这个患者群体中确定与改善生存结果相关的治疗模式.

主要方法:

从2000年至2020年间从SEER数据库中对482名被诊断患有T4b期食道癌的患者进行了回顾性分析.
卡普兰-梅尔分析和多变量比例危险回归被用来比较跨治疗组的癌症特异性生存率 (CSS) 和整体生存率 (OS).
倾向性得分匹配被用来最大限度地减少治疗组之间的混因素.

主要成果:

与化学辐射疗法相比,手术显示出明显更好的CSS (HR=0.42,P=0.002) 和OS (HR=0.45,P=0.002).
接受手术的患者的中位数CSS为18个月,OS为17个月,而化学放射治疗的CSS为12个月和OS为11个月.
非治疗产生了最差的结果,中位数的CSS和OS为1个月.

结论:

带有或没有辅助疗法的食管切除术与T4b期食管癌的优异生存结果有关.
目前的研究结果表明,在符合条件的患有T4b期食道癌的患者中,应强烈考虑进行外科手术.

关键词:

在T4b中,它是T4b.这是食道癌的癌症.幸存率幸存率生存率治疗模式治疗模式

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Barrett Esophagus-II: Clinical Manifestations and Management

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

Barrett Esophagus-I: Introduction

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...